Please select the option that best describes you:
For a patient with distal esophageal adenocarcinoma with residual disease after FOLFOX x3 cycles + RT followed by surgery, would you recommend adjuvant chemotherapy or adjuvant nivolumab?
Would you ever consider adjuvant chemotherapy rather than adjuvant immunotherapy after the publication of the CM-577 results?
If so, in which populations and which regimen?
Answer from: Medical Oncologist at Academic Institution
CM577 has simultaneously done 2 things: established nivolumab as a standard-of-care in this setting but also hopefully discourages/eliminates the use of adjuvant chemotherapy. There are absolutely no data to justify giving more or different chemotherapy to such patients. Remember, the control arm of...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I'm going to assume that you're referring to residual pathologic disease. In this scenario (neoadjuvant chemoradiation followed by surgery), there is no evidence that adjuvant chemotherapy can reduce the risk of recurrence. I would recommend adjuvant nivolumab based on the reported CM577 data. This ...
Comments
Medical Oncologist at Springfield Clinic Hem/Onc
Yes, it's pathologic residual disease. Thanks for ...
Yes, it's pathologic residual disease. Thanks for ...
Answer from: Medical Oncologist at Community Practice
I would consider adj Nivolumab, but only in CPS >5%, since subgroup analysis (appendix of the NEJM publication) showed little to no benefit outside this subgroup.
Comments
Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
If the question was, "For a patient with distal es...
If the question was, "For a patient with distal es...